Breaking News Bar

Business News and Information

Alimera Sciences Inc. (NASDAQ: ALIM) Featured in Virtual Coverage of The LD 500

Alimera Sciences Inc. (NASDAQ: ALIM) is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people globally. Alimera recently initiated the company’s Phase 4 NEW DAY clinical trial, a randomized, controlled, multi-center study designed to generate prospective data for ILUVIEN(R) (fluocinolone acetonide intravitreal implant) 0.19 mg as a baseline therapy in patients diagnosed with diabetic macular edema (DME).For more information, visit the company’s website at www.alimerasciences.com

To register for The LD 500 and watch the live presentation, visit http://ibn.fm/TheLD500Registration

To view IBN’s virtual coverage of The LD 500, visit https://ibn.fm/TheLD500

About InvestorBrandNetwork’s Virtual Coverage

The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating virtually at The LD 500. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of next month’s The LD 500.

For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its many event collaborations in 2020, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear